Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Pentaglobin After Source Control in Peritonitis Patients
2024-513526-27-00Phase 2Authorised
- Sponsor
- University Hospital RWTH Aachen
- Start
- May 2024
- Modality
- Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial in secondary peritonitis, peritonitis, sepsis and 1 more comparing Pentaglobin plus standard of care with Standard of care (2 arms). Primary endpoint: Change in multiple organ failure (MOF) score from baseline to day 7. Planned start May 2024; status: authorised.
02
Drugs
Pentaglobin
03
Conditions
secondary peritonitisperitonitissepsisseptic shock
Beyond the preview
Go deeper on 2024-513526-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513526-27-00.